Jakub Gołąb

ORCID: 0000-0002-2830-5100
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Immune cells in cancer
  • Cancer Research and Treatments
  • Ubiquitin and proteasome pathways
  • Adenosine and Purinergic Signaling
  • Nanoplatforms for cancer theranostics
  • Immune Cell Function and Interaction
  • Immunotherapy and Immune Responses
  • Photodynamic Therapy Research Studies
  • Endoplasmic Reticulum Stress and Disease
  • Cancer, Lipids, and Metabolism
  • Monoclonal and Polyclonal Antibodies Research
  • Retinoids in leukemia and cellular processes
  • Receptor Mechanisms and Signaling
  • Chronic Lymphocytic Leukemia Research
  • Retinal Diseases and Treatments
  • Peptidase Inhibition and Analysis
  • Cancer Mechanisms and Therapy
  • Lymphoma Diagnosis and Treatment
  • Phagocytosis and Immune Regulation
  • Cancer, Hypoxia, and Metabolism
  • CAR-T cell therapy research
  • Autophagy in Disease and Therapy
  • RNA Interference and Gene Delivery
  • Protein Degradation and Inhibitors
  • Angiogenesis and VEGF in Cancer

Medical University of Warsaw
2016-2025

OncoArendi Therapeutics (Poland)
2017-2024

Institute of Physical Chemistry
2009-2020

Polish Academy of Sciences
2009-2020

Gdańsk Medical University
2019

Warsaw University of Technology
2010-2019

Postgraduate School of Molecular Medicine
2019

University of Warsaw
2018-2019

National Cancer Institute
2019

Institute of Neuroimmunology of the Slovak Academy of Sciences
2004-2009

The immunogenicity of malignant cells has recently been acknowledged as a critical determinant efficacy in cancer therapy. Thus, besides developing direct immunostimulatory regimens, including dendritic cell-based vaccines, checkpoint-blocking therapies, and adoptive T-cell transfer, researchers have started to focus on the overall immunobiology neoplastic cells. It is now clear that can succumb some anticancer therapies by undergoing peculiar form cell death characterized an increased...

10.3389/fimmu.2015.00588 article EN cc-by Frontiers in Immunology 2015-11-20

Tumor-driven immune suppression is a major barrier to successful immunotherapy in ovarian carcinomas (OvCa). Among various mechanisms responsible for suppression, arginase-1 (ARG1)-carrying small extracellular vesicles (EVs) emerge as important contributors tumor growth and escape from the host system. Here, we report that EVs found ascites plasma of OvCa patients contain ARG1. suppress proliferation CD4+ CD8+ T-cells vitro vivo mouse models. In mice, ARG1-containing are transported draining...

10.1038/s41467-019-10979-3 article EN cc-by Nature Communications 2019-07-05

Aminolevulinic acid (ALA) is an endogenous metabolite normally formed in the mitochondria from succinyl-CoA and glycine. Conjugation of eight ALA molecules yields protoporphyrin IX (PpIX) finally leads to formation heme. Conversion PpIX its downstream substrates requires activity a rate-limiting enzyme ferrochelatase. When administered externally abundantly produced cannot be quickly converted final product - heme by ferrochelatase therefore accumulates within cells. Since potent...

10.3390/molecules16054140 article EN cc-by Molecules 2011-05-19

Photodynamic therapy (PDT) is a clinically approved and rapidly developing cancer treatment regimen. It minimally invasive two-stage procedure that requires administration of photosensitizing agent followed by illumination the tumor with visible light usually generated laser sources. A third component PDT molecular oxygen which required for most effective antitumor effects. In presence latter, an appropriate wavelength excites photosensitizer thereby producing cytotoxic intermediates damage...

10.18388/abp.2005_3447 article EN cc-by Acta Biochimica Polonica 2005-06-25

Statins, which have been introduced to the clinic for treatment of hypercholesterolemia, are competitive inhibitors 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, major rate-limiting enzyme that controls conversion HMG-CoA mevalonic acid (MA). MA is precursor in biosynthesis isoprenoid compounds including cholesterol, dolichol and ubiquinone. Furthermore, mevalonate-derived prenyl groups enable precise cellular localization function many proteins such as Ras Rho proteins....

10.3892/ijo.23.4.1055 article EN International Journal of Oncology 2003-10-01

Systemic chemotherapy generally has been considered immunosuppressive, but it become evident that certain chemotherapeutic drugs elicit immunogenic danger signals in dying cancer cells can incite protective antitumor immunity. In this study, we investigated whether locoregionally applied therapies, such as melphalan, used limb perfusion for melanoma (Mel-ILP) produce related effects. human biopsies, Mel-ILP treatment upregulated IL1B, IL8, and IL6 associated with their release patients'...

10.1158/0008-5472.can-14-2089 article EN Cancer Research 2015-03-12

Eukaryotic mRNAs undergo cotranscriptional 5′-end modification with a 7-methylguanosine cap. In higher eukaryotes, the cap carries additional methylations, such as m6Am─a common epitranscriptomic mark unique to mRNA 5′-end. This is regulated by Pcif1 methyltransferase and FTO demethylase, but its biological function still unknown. Here, we designed synthesized trinucleotide FTO-resistant N6-benzyl analogue of m6Am-cap–m7GpppBn6AmpG (termed AvantCap) incorporated it into using T7 polymerase....

10.1021/jacs.3c12629 article EN cc-by Journal of the American Chemical Society 2024-03-05

Abstract Purpose: The unique mechanism of tumor destruction by photodynamic therapy (PDT), resulting from apoptotic and necrotic killing cells accompanied local inflammatory reaction induction heat shock proteins (HSPs), prompted us to investigate the antitumor effectiveness combination PDT with administration immature dendritic (DCs). Experimental Design: Confocal microscopy Western blotting were used influence on apoptosis expression HSP in C-26 cells. flow cytometry studies examine...

10.1158/1078-0432.ccr-04-0367 article EN Clinical Cancer Research 2004-07-01

Background Rituximab is used in the treatment of CD20+ B cell lymphomas and other lymphoproliferative disorders. Its clinical efficacy might be further improved by combinations with drugs such as statins that inhibit cholesterol synthesis show promising antilymphoma effects. The objective this study was to evaluate influence on rituximab-induced killing lymphomas. Methods Findings Complement-dependent cytotoxicity (CDC) assessed MTT Alamar blue assays well trypan staining, antibody-dependent...

10.1371/journal.pmed.0050064 article EN cc-by PLoS Medicine 2008-03-19

Photodynamic therapy (PDT) is an approved therapeutic procedure that exerts cytotoxic activity toward tumor cells by inducing production of reactive oxygen species such as singlet oxygen. PDT leads to oxidative damage cellular macromolecules, including proteins undergo multiple modifications fragmentation, cross-linking, and carbonylation result in protein unfolding aggregation. Because the major mechanism for elimination carbonylated their degradation proteasomes, we hypothesized a...

10.1158/0008-5472.can-08-3439 article EN Cancer Research 2009-05-13

10.1039/c0pp00308e article EN Photochemical & Photobiological Sciences 2011-01-24

Thiosemicarbazones (TSCs) are an interesting class of ligands that show a diverse range biological activity, including anti-fungal, anti-viral and anti-cancer effects. Our previous studies have demonstrated the potent in vivo anti-tumor activity novel TSCs their ability to overcome resistance clinically used chemotherapeutics. In current study, 35 6 different classes were designed using combination retro-fragments appear other TSCs. Additionally, di-substitution at terminal N4 atom, which...

10.1371/journal.pone.0110291 article EN cc-by PLoS ONE 2014-10-16

Abstract Examination of whole organs with subcellular resolution in health, disease, and during development is necessary to decipher their biological complexity. However, until recently, this has been virtually impossible due the natural opacity organ tissue. Recent progress tissue optical clearing (TOC) overcome limitation by turning into transparent, light‐permitting specimens. At least 20 original TOC methods have developed less than a decade, which were followed hundreds attempts that...

10.1002/lpor.201800292 article EN cc-by-nc Laser & Photonics Review 2019-07-15
Coming Soon ...